These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

617 related items for PubMed ID: 15847853

  • 1. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR.
    Am J Cardiol; 2005 May 02; 95(9A):14B-23B. PubMed ID: 15847853
    [Abstract] [Full Text] [Related]

  • 2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 May 02; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism.
    Rai A, Whaley-Connell A, McFarlane S, Sowers JR.
    Am J Nephrol; 2006 May 02; 26(6):579-89. PubMed ID: 17170524
    [Abstract] [Full Text] [Related]

  • 5. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1322-30. PubMed ID: 18179782
    [Abstract] [Full Text] [Related]

  • 6. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C, Pistrosch F, Herbrig K, Gross P.
    Am J Med; 2006 Jul 15; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment options for hyponatremia in heart failure.
    Goldsmith SR.
    Congest Heart Fail; 2010 Jul 15; 16 Suppl 1():S15-8. PubMed ID: 20653706
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1615-21. PubMed ID: 16630999
    [Abstract] [Full Text] [Related]

  • 11. Hyponatremia: current treatment strategies and the role of vasopressin antagonists.
    Cawley MJ.
    Ann Pharmacother; 2007 May 18; 41(5):840-50. PubMed ID: 17405824
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam ZS, Abu-Saleh N, Nitecki S, Winaver J, Hoffman A, Abassi ZA.
    J Pharmacol Exp Ther; 2008 Aug 18; 326(2):414-22. PubMed ID: 18467593
    [Abstract] [Full Text] [Related]

  • 14. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP, Balk RA.
    Clin Ther; 2007 Feb 18; 29(2):211-29. PubMed ID: 17472815
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 18. Vasopressin: a new target for the treatment of heart failure.
    Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF.
    Am Heart J; 2003 Jul 03; 146(1):9-18. PubMed ID: 12851603
    [Abstract] [Full Text] [Related]

  • 19. Vasopressin excess and hyponatremia.
    Pham PC, Pham PM, Pham PT.
    Am J Kidney Dis; 2006 May 03; 47(5):727-37. PubMed ID: 16632011
    [Abstract] [Full Text] [Related]

  • 20. Vaptans and the treatment of water-retaining disorders.
    Quittnat F, Gross P.
    Semin Nephrol; 2006 May 03; 26(3):234-43. PubMed ID: 16713496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.